menu
    • menu
    [{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Merck"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Pfizer"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Nortec Quimica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"The Medicines Patent Pool \/ The Medicines Patent Pool","highestDevelopmentStatusID":"9","companyTruncated":"The Medicines Patent Pool \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"The Medicines Patent Pool \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"MedinCell","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ivermectin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"The Medicines Patent Pool \/ Medicines Patent Pool","highestDevelopmentStatusID":"4","companyTruncated":"The Medicines Patent Pool \/ Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"The Medicines Patent Pool \/ The Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Nilotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"The Medicines Patent Pool \/ Strides Pharma Science","highestDevelopmentStatusID":"12","companyTruncated":"The Medicines Patent Pool \/ Strides Pharma Science"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"14","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by The Medicines Patent Pool

    Menu

    The Medicines Patent Pool

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Aurobindo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug

                            Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.

                            Brand Name : Tasigna-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 23, 2023

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Aurobindo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : ViiV Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medicines Patent Pool Signs Sublicences With Aurobindo, Cipla and Viatris to Produce Generic Versions of ViiV ...

                            Details : Through the agreement, the selected generic manufacturers, Aurobindo, Cipla and Viatris, will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP, in 90 countries, subject to required regulatory approvals being obtain...

                            Brand Name : Cabotegravir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : ViiV Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Med Patent Pool Signs with Aurobindo, Cipla & Viatris for Generic HIV Prevention Medicine

                            Details : ViiV Healthcare sublicence agreements with Aurobindo, Cipla and Viatris to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis.

                            Brand Name : Apretude-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : MedinCell

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of I...

                            Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.

                            Brand Name : mdc-STM

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 13, 2022

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : MedinCell

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : ViiV Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innov...

                            Details : Through this agreement, selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP, the first long-acting HIV prevention medicine, in 90 countries, subject to regulatory approv...

                            Brand Name : Cabotegravir LA-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 28, 2022

                            Lead Product(s) : Cabotegravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : ViiV Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Nortec Quimica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nortec Química Receives License From The Medicines Patent Pool (MPP) to Produce API Nirmatrelvir for Innovati...

                            Details : With this agreement, the active pharmaceutical ingredient nirmatrelvir can be fully manufactured in Brazil by Nortec, ensuring safety and adherence to treatment for countries such as: South Africa, Tanzania, Venezuela, Bolivia, Ethiopia, Haiti, Honduras,...

                            Brand Name : Nirmatrelvir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Nortec Quimica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Strides Partners with Medicines Patent Pool (MPP) to Commercialize the Generic Version of Pfizer’s COVID-19 ...

                            Details : The agreement aims to commercialize a generic version of Pfizer’s COVID-19 oral treatment, Paxlovid (nirmatrelvir and ritonavir), indicated for the treatment of mild-to-moderate coronavirus disease, in 95 low and middle-income markets.

                            Brand Name : Paxlovid-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 21, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Strides Pharma Science

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            35 Generic Manufacturers Sign Agreements With MPP to Produce Low-Cost, Generic Versions of Pfizer's Oral COVID...

                            Details : Sublicences will allow manufacturers (Teva, Cipla, Biocon, Amneal, Viatris, Torrent, MSN, Sun Pharma, Cadila, Glenmark, Fosun, Beximco, Celltrion & others) to produce the raw materials for generic of Pfizer’s COVID-19 nirmatrelvir and finished drug co-...

                            Brand Name : Nirmatrelvir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 17, 2022

                            Lead Product(s) : Nirmatrelvir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Natco Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Natco Pharma Signs Pact With MPP to Sell Molnupiravir Capsules

                            Details : This agreement allows Natco to expand access to COVID-19 medicines in 105 countries in generic name. Under the licence, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD.

                            Brand Name : Molnunat

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 20, 2022

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Natco Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            The Medicines Patent Pool

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Biophore India Pharmaceuticals Pvt Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biophore Receives Sub-License From MPP to Manufacture and Market Molnupiravir for Covid Treatment

                            Details : The licences are applicable for both molnupiravir (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a s...

                            Brand Name : MK-4482

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 20, 2022

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Biophore India Pharmaceuticals Pvt Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth